Skip To Main Content
Salong Debbarma on Muck Rack

Salong Debbarma

United Kingdom
As seen in: Clinical Trials Arena, GlobalData, Pharmaceutical Technology, MSN, MSN Italy, Yahoo Life, Yahoo Finance, Flipboard, Yahoo, The Hans India, Power Technology, Offshore Technology, Pharmaceutical-Technology.com and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Salong

Contact Salong, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Optellum and Coreline Soft plan AI integration for lung nodule care

|
By Salong Debbarma
| hospitalmanagement.net Verified
The LungOS platform is designed for screening incidental lung nodules. Credit: create jobs 51/Shutterstock.com. Optellum and Coreline Soft have announced plans to integrate AI to support lung nodule detection and management across international markets and multiple disease areas. Under the partnership, Coreline Soft’s Food and Drug Administration (FDA)-cleared computer-aided detection (CADe) software, AVIEW Lung Nodule CAD, will be made available on Optellum’s AI-powered LungOS platform.
Open in Who Shared Issue with article?

SCRI and MSD to broaden US oncology trial access

|
By Salong Debbarma
| hospitalmanagement.net Verified
The organisations aim to implement efficient trial delivery approaches and use advanced data methods. Credit: Gorodenkoff / Shutterstock.com. Sarah Cannon Research Institute (SCRI) and Merck & Co (MSD) have entered a collaboration aimed at increasing patient access to oncology clinical trials at community sites across the US. The partnership will utilise SCRI’s Accelero delivery model, which is designed to improve both the reach and efficiency of cancer studies.
Open in Who Shared Issue with article?

Distalmotion receives FDA 510(k) clearance for Dexter robotic system Original

|
By Salong Debbarma
| Medical Device Network Verified
Dexter is permitted in four highest-volume US ambulatory procedures. Credit: Distalmotion SA / GlobeNewswire. Distalmotion has received 510(k) clearance from the US Food and Drug Administration (FDA) for ventral hernia repair with its Dexter robotic surgery system. The approval is backed by information from the Robotic Minimally Invasive Ventral Hernia Repair (RAVEN) study.
Open in Who Shared View Duplicates (3) Issue with article?
See all 5,031 articles